Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy

Overview of attention for article published in Blood Advances, May 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 9 X users

bluesky: 4 Bluesky users

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 9 X posts from 9 X users, with an upper bound of 7,653 followers.

Featured today by @MSKLibrary: Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy https://t.co/fcXQ5DMjlx #MPNResearch #AMLInsights #HemeOnc #LeukemiaResearch #RiskStratification #LessInt…

RT @UChicagoHemOnc: More great research coming from our @UCHemOncFellows!! Drs. Shaw, Cannova, Johnston, and Madero-Marroquin in @BloodAdva…

RT @UChicagoLeuk: New work led by @Anand_88_Patel featuring @HJohnstonMD as co-author in @BloodAdvances evaluating the use of AML risk crit…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.